摘要
目的:系统评价非洛地平联合美托洛尔对比单用非洛地平治疗高血压的疗效与安全性,以为临床提供循证参考。方法:计算机检索PubMed、Medline(OVID)、EMBase、中国期刊全文数据库、中文科技期刊全文数据库、万方数据库,按照纳入和排除标准,制定检索策略,全面收集非洛地平联合美托洛尔对比单用非洛地平治疗高血压的随机对照试验(RCT),对纳入研究进行质量评价和资料提取后,采用Rev Man 5.0统计软件进行Meta分析。结果:共纳入18项RCT,包括2 059例患者。Meta分析结果显示,试验组患者总有效率显著高于对照组[OR=5.35,95%CI(3.90,7.34),P<0.000],不良反应发生率显著低于对照组[OR=0.69,95%CI(0.48,0.98),P=0.04],差异均有统计学意义。结论:非洛地平联合美托洛尔治疗高血压的疗效与安全性均好于单用非洛地平。由于纳入的研究质量差异较大,该结论有待高质量的RCT进一步验证。
OBJECTIVE： To evaluate therapeutic efficacy and safety of metoprolol combined with felodipine versus felodipine alone in the treatment of hypertension, and to provide evidence-based reference for clinical use. METHODS： Retrieved from Pubmed, Medline（ovid）, EMbase, CNKI, Chinese Scientific Journals Database, Wanfang database, according to the inclusion and exclusion criteria, search strategies were developed to collect RCTs about metoprolol combined with felodipine in the treatment of hypertension. Meta-analysis was performed by using Rev Man 5.0 statistical software after evaluating the quality of included stud- ies and extracting data. RESULTS： A total of 18 RCTs included, involving 2 059 patients. Meta-analysis showed that the total effec- tive rate of trial group was higher than control group [OR=5.35, 95%CI （3.90, 7.34）, P〈0.000] and the incidence of ADR was significantly lower than in control group[OR=0.69, 95%CI（0.48, 0.98）, P=0.04]; there was statistical significance. CONCLUSIONS： Felodipine combined with metoprolol is more effective and safer than felodipine alone for hypertension. Due to great quality difference of included studies, high quality RCT are required to further validate above conclusions.
出处
《中国药房》
CAS
CSCD
2014年第32期2987-2990,共4页
China Pharmacy
基金
"十二五"国家科技支撑计划项目(No.2013BAI06B04)
